This is consistent with findings that sorbitol dehydrogenase inhibitors fail to increase nerve blood flow or conduction velocity in experimental diabetes [44] but instead worsen nerve energy status in some studies [45], and apparently exacerbate sympathetic autonomic neuropathy in STZ-induced diabetes [46]. Here, SORD is linked to diabetes mellitus.